PE20240141A1 - Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares - Google Patents

Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares

Info

Publication number
PE20240141A1
PE20240141A1 PE2023000820A PE2023000820A PE20240141A1 PE 20240141 A1 PE20240141 A1 PE 20240141A1 PE 2023000820 A PE2023000820 A PE 2023000820A PE 2023000820 A PE2023000820 A PE 2023000820A PE 20240141 A1 PE20240141 A1 PE 20240141A1
Authority
PE
Peru
Prior art keywords
atorvastatin
prevention
treatment
cardiovascular diseases
fenofibrate
Prior art date
Application number
PE2023000820A
Other languages
English (en)
Inventor
Rubio Paola Yazmin Ollervides
Canudas Jorge Alejandro Gonzales
Leon Sixto Serafin Espinoza
Salazar Claudia Delfina Farfan
Original Assignee
Laboratorios Silanes S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Silanes S A De C V filed Critical Laboratorios Silanes S A De C V
Publication of PE20240141A1 publication Critical patent/PE20240141A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion farmaceutica caracterizada porque comprende: (a) atorvastatina, o una sal de la misma (20 ± 0.7 mg), y (b) fenofibrato micronizado, o su sal micronizada, (160 mg y 200 mg), y (c) excipientes y/o vehiculos farmaceuticos aceptables. Esta composicion permite combinar la atorvastatina y el fenofibrato en una unica forma farmaceutica solida, estable y de liberacion inmediata, la cual se emplea en el tratamiento de hiperlipidemias y prevencion de enfermedades cardiovasculares. Tambien se refiere a un proceso de obtencion, el cual incluye una etapa de granulacion activada por calentamiento con fenofibrato; una etapa de incorporacion de la atorvastatina; una etapa de compresion y en donde el proceso se efectua sin la incorporacion de agua evitando condiciones que afectan la estabilidad de la atorvastatina.
PE2023000820A 2020-09-29 2020-09-29 Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares PE20240141A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2020/050034 WO2022071787A1 (es) 2020-09-29 2020-09-29 Combinaciones farmacéuticas de estatinas y fibratos para el tratamiento y prevención de hiperlipidemias y enfermedades cardiovasculares

Publications (1)

Publication Number Publication Date
PE20240141A1 true PE20240141A1 (es) 2024-02-01

Family

ID=80951574

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023000820A PE20240141A1 (es) 2020-09-29 2020-09-29 Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares

Country Status (11)

Country Link
US (1) US20230355578A1 (es)
EP (1) EP4180036A4 (es)
JP (1) JP2023543565A (es)
KR (1) KR20230079187A (es)
BR (1) BR112023005247A2 (es)
CA (1) CA3191478A1 (es)
CO (1) CO2023004367A2 (es)
DO (1) DOP2023000043A (es)
MX (1) MX2022015336A (es)
PE (1) PE20240141A1 (es)
WO (1) WO2022071787A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1415295A (en) 1971-10-14 1975-11-26 Orchimed Sa Substituted phenoxy-alkyl-carboxylic acids and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US20070014846A1 (en) * 2003-10-10 2007-01-18 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
KR20060085682A (ko) * 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트 및 스타틴을 함유하는 고형 제제
CN100551363C (zh) * 2003-10-10 2009-10-21 生命周期药物公司 包含贝特的固体剂型
CA2582403A1 (en) 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
MX2007009281A (es) * 2005-02-10 2007-09-25 Lufecycle Pharma As Composicion farmaceutica estable que comprende una combinacion de dosis fija de fenofibrato y un inhibidor de 3-hidroxi 3-metilglutaril-coenzima a reductasa.
CN101115478A (zh) * 2005-02-10 2008-01-30 生命周期药物公司 包含非诺贝特和HMG-CoA还原酶抑制剂的固定剂量组合的稳定药物组合物
EP1818049A3 (en) * 2006-02-10 2008-11-19 LifeCycle Pharma A/S Stabilized Atorvastatin
CN102083422A (zh) 2008-07-03 2011-06-01 万能药生物有限公司 口服生物利用度提高的非诺贝特制剂
EP2341773A4 (en) 2008-09-24 2012-03-07 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN
CN102188419A (zh) 2010-03-12 2011-09-21 上海天龙药业有限公司 包含非诺贝特和阿托伐他汀的单个制剂
CN103702982A (zh) 2011-07-01 2014-04-02 中化帝斯曼制药有限公司荷兰公司 阿托伐他汀半钙的超细晶体
MX2013006332A (es) 2013-06-05 2014-12-19 Alparis Sa De Cv Composiciones farmaceuticas orales para uso en dislipidemias.
BR102013028912A2 (pt) * 2013-11-08 2017-02-14 Hypermarcas S A composição farmacêutica, forma farmacêutica oral, cápsula, comprimido de dupla camada, usos, método de tratamento de hipercolesterolemia, hipertrigliceridemia e/ou dislipidemia mista e método de prevenção de aterosclerose, diabetes ou prevenção secundária de outras doenças cardiovasculares

Also Published As

Publication number Publication date
EP4180036A1 (en) 2023-05-17
WO2022071787A1 (es) 2022-04-07
CO2023004367A2 (es) 2023-05-29
DOP2023000043A (es) 2023-04-30
EP4180036A4 (en) 2024-01-31
US20230355578A1 (en) 2023-11-09
BR112023005247A2 (pt) 2023-04-25
MX2022015336A (es) 2023-01-11
JP2023543565A (ja) 2023-10-17
CA3191478A1 (en) 2022-04-07
KR20230079187A (ko) 2023-06-05

Similar Documents

Publication Publication Date Title
AR059575A1 (es) Metodo para el tratamiento de enfermedades inflamatorias
CL2022000997A1 (es) Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto. (divisional de solicitud 202100645)
EA202190547A1 (ru) Способы снижения потребности в реваскуляризации периферических артерий у субъекта, получающего лечение статинами
CR9721A (es) Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos
TNSN07482A1 (fr) Nouvelles compositions injectables et procede de preparation desdites compositions
PE20220751A1 (es) Composiciones solidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico
EA200701746A1 (ru) Фармацевтические композиции для лечения или профилактики заболеваний, в том числе ожирения, диабета, метаболического синдрома, нейродегенеративных заболеваний и заболеваний, связанных с нарушением деятельности митохондрий
EA200800064A1 (ru) Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
MA37850A1 (fr) Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
EA200870469A1 (ru) Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
RU2007119641A (ru) Композиция, включающая ацетаминофен, кофеин и необязательно аспирин в смеси со щелочным агентом для увеличения абсорбции
Bashyal Ibuprofen and its different analytical and manufacturing methods: a review
PE20240141A1 (es) Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares
ATE480229T1 (de) Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung
NZ599268A (en) Pharmaceutical compositions of rhein or diacerein made by wet granulation process
AR075037A1 (es) Composiciones farmaceuticas de rendimiento de producto y cumplimiento del paciente superiores
AR022856A1 (es) Acido abierto dihidroxi y sales de inhibidores de hmg-co-a reductasa
EA202192118A1 (ru) Фармацевтическая композиция, содержащая ацетаминофен и ибупрофен
Patel et al. Evaluation of anti-inflammatory, analgesic, and antipyretic effects of ethanolic extract of Pedalium murex Linn. fruits
RU2019110264A (ru) Циклическое соединение
MA63879B1 (fr) Conjugué de paclitaxel et d'acide hyaluronique dans le traitement du cancer de la vessie sans infiltration du muscle
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
UY31363A1 (es) Composiciones farmaceuticas que comprenden la combinacion de un agente antiflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa utiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas
RU2019102890A (ru) Фармацевтические композиции, содержащие флурбипрофен